[High-dose intravitreal ganciclovir in CMV retinitis].
OBJECTIVE
To assess the efficacy and tolerability of high-dose (2000microg) intravitreous ganciclovir in the maintenance therapy of CMV retinitis in AIDS patients.


METHODS
and methods: Prospective open study in a single center. The maintenance therapy of CMV retinitis consisted of a single high-dose (2000microg) intravitreous injection per week. The evaluation criteria were clinical examinations, and photographs when necessary.


RESULTS
Over a 44-week period, twenty-four eyes (15 patients) have been included. The relapse rate evaluated by the survival curves method was 5% at 44 weeks. No ocular toxicity was reported after a follow-up of 24 weeks.


CONCLUSIONS
High-dose intravitreous ganciclovir induces a prolonged remission of CMV retinitis and is well tolerated. Therefore, we recommend the use of the 2000microg dosage per intravitreous injection instead of the classical dosage of 400microg.
Cochereau
I
I
Service d'Ophtalmologie, Hôpital Bichat, Paris. oph.sec@bch.ap-hop-paris.fr
Diraison
M C
MC
Mousalatti
H
H
Bouyer
I
I
Ren
L
L
Guvenisik
N
N
Hoang-Xuan
T
T
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D014822:Vitreous Body / Q000187:drug effects
D000998:Antiviral Agents; D015774:Ganciclovir